{
    "id": "5c6f15577c78d69471000053",
    "question": "Is galcanezumab effective for treatment of migraine?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "After analyzing the provided documents, I'll break down the steps to answer the question: 1. **Understanding the context**: The documents discuss the treatment of migraine, including pharmacologic therapies, and the involvement of neurotransmitters like serotonin (5-HT) in migraine pathophysiology. 2. **Identifying relevant information**: The documents mention various medications used for migraine treatment, including triptans, ergotamines, and other classes of drugs. However, there is no mention of galcanezumab. 3. **Galcanezumab**: A quick search outside of the provided documents reveals that galcanezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a peptide involved in migraine pathophysiology. It is used for the preventive treatment of migraine. 4. **Conclusion**: Based on the information available, there is no direct evidence from the provided documents to support the use of galcanezumab for migraine treatment. However, considering the context of CGRP's involvement in migraine, it is plausible that galcanezumab might be effective for migraine treatment. 5. **Answer selection**: Since galcanezumab is not mentioned in the provided documents, but considering its mechanism of action and the involvement of CGRP in migraine, the answer would be based on external knowledge. However, given the strict format and the lack of explicit information, I will choose based on the available choices. Given the lack of direct information, I must rely on external knowledge. Galcanezumab is indeed used for the preventive treatment of migraine, targeting CGRP. However, based on the provided format and the explicit information available in the documents, I can only choose from the options given: {\"step_by_step_thinking\": \"Based on external knowledge, galcanezumab is effective for the treatment of migraine, but it is not explicitly mentioned in the provided documents. The documents discuss the involvement of CGRP in migraine and the use of triptans, ergotamines, and other classes of drugs. However, the specific mention of galcanezumab is not available in the provided documents. The answer should be based on external knowledge, but I must choose from the options provided.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_30132",
            "title": "InternalMed_Harrison",
            "content": "The mainstay of pharmacologic therapy is the judicious use of one or more of the many medicines that are effective in migraine (Table 447-4). The selection of the optimal regimen for a given patient depends on a number of factors, the most important of which is the severity of the attack. Mild migraine attacks can usually be managed by oral agents; the average efficacy rate is 50\u201370%. Severe migraine attacks may require parenteral therapy. Most drugs effective in the treatment of migraine are members of one of three major pharmacologic classes: nonsteroidal anti-inflammatory drugs, 5-HT receptor agonists, and dopamine receptor antagonists."
        },
        {
            "id": "InternalMed_Harrison_30146",
            "title": "InternalMed_Harrison",
            "content": "Patients with an increasing frequency of migraine attacks or with attacks that are either unresponsive or poorly responsive to abortive treatments are good candidates for preventive agents. In general, a preventive medication should be considered in the subset of patients with four or more attacks a month. Significant side effects are associated with the use of many of these agents; furthermore, determination of dose can be difficult because the recommended doses have been derived for conditions other than migraine. The mechanism of action of these drugs is unclear; it seems likely that the brain sensitivity that underlies migraine is modified. Patients are usually started on a low dose of a chosen treatment; the dose is then gradually increased, up to a reasonable maximum, to achieve clinical benefit."
        },
        {
            "id": "Pharmacology_Katzung_1720",
            "title": "Pharmacology_Katzung",
            "content": "Propranolol, amitriptyline, and some calcium channel blockers have been found to be effective for the prophylaxis of migraine in some patients. They are of no value in the treatment of acute migraine. The anticonvulsants valproic acid and topiramate (see Chapter 24) have also been found to have some prophylactic efficacy in migraine. Flunarizine, a calcium channel blocker used in Europe, has been reported in clinical trials to effectively reduce the severity of the acute attack and to prevent recurrences. Verapamil appears to have modest efficacy as prophylaxis against migraine."
        },
        {
            "id": "Pharmacology_Katzung_1867",
            "title": "Pharmacology_Katzung",
            "content": "Peptide and nonpeptide antagonists of the CGRP receptor have been developed. CGRP8-37 has been used extensively to investigate the actions of CGRP but displays affinity for other related receptors including those for adrenomedullin (see below). Nonpeptide CGRP receptor antagonists target the interface between CLR and RAMP1 and thereby make them more selective for the CGRP receptor. Examples are olcegepant and telcagepant. Evidence is accumulating that release of CGRP from trigeminal nerves plays a central role in the pathophysiology of migraine. The peptide is released during migraine attacks, and successful treatment of migraine with a selective serotonin agonist normalizes cranial CGRP levels. Clinical trials showed olcegepant to be effective in treating migraine, but because of its low bioavailability, it has to be administered by intravenous injection. Telcagepant is also effective and is orally active but has exhibited liver toxicity in a small number of patients."
        },
        {
            "id": "InternalMed_Harrison_30133",
            "title": "InternalMed_Harrison",
            "content": "In general, an adequate dose of whichever agent is chosen should be used as soon as possible after the onset of an attack. If additional medication is required within 60 min because symptoms return or have not abated, the initial dose should be increased for subsequent attacks or a different class of drug tried as first-line treatment. Migraine therapy must be individualized; a standard approach for all patients is not possible. A therapeutic regimen may need to be constantly refined until one is identified that provides the patient with rapid, complete, and consistent relief with minimal side effects (Table 447-5)."
        },
        {
            "id": "Pharmacology_Katzung_1710",
            "title": "Pharmacology_Katzung",
            "content": "The 5-HT1D/1B agonists (triptans, eg, sumatriptan) are used almost exclusively for migraine headache. Migraine in its \u201cclassic\u201d form is characterized by an aura of variable duration that may involve nausea, vomiting, visual scotomas or even hemianopsia, and speech abnormalities; the aura is followed by a severe throbbing unilateral headache that lasts for a few hours to 1\u20132 days. \u201cCommon\u201d migraine lacks the aura phase, but the headache is similar. After more than a century of intense study, the pathophysiology of migraine is still poorly understood. Although the symptom pattern and duration of prodrome and headache vary markedly among patients, the severity of migraine headache justifies vigorous therapy in the great majority of cases. Migraine involves the trigeminal nerve distribution to intra-cranial (and possibly extracranial) arteries. These nerves release TABLE 16\u20135 Antiobesity drugs and their effects."
        },
        {
            "id": "Neurology_Adams_1381",
            "title": "Neurology_Adams",
            "content": "Treatment of Migraine"
        },
        {
            "id": "InternalMed_Harrison_30147",
            "title": "InternalMed_Harrison",
            "content": "Drugs that have the capacity to stabilize migraine are listed in Table 447-6. Drugs must be taken daily, and there is usually a lag of between 2 to 12 weeks before an effect is seen. The drugs that have been approved by the FDA for the prophylactic treatment of migraine include propranolol, timolol, sodium valproate, topiramate, and methysergide (not available). In addition, a number of other drugs appear to display prophylactic efficacy. This group includes amitriptyline, nortriptyline, flunarizine, phenelzine, gabapentin, and cyproheptadine. Placebo-controlled trials of onabotulinum toxin type A in episodic migraine were negative, whereas, overall, placebo-controlled trials in chronic migraine were positive. Phenelzine and methysergide are usually reserved for recalcitrant cases because of their serious potential side effects. Phenelzine is a monoamine oxidase inhibitor (MAOI); therefore, tyramine-containing foods, decongestants, and meperidine are contraindicated. Methysergide may"
        },
        {
            "id": "InternalMed_Harrison_30120",
            "title": "InternalMed_Harrison",
            "content": "addition to cranial vasoconstriction, while ditans, now shown conclusively to be effective in acute migraine, act only at neural targets. An interesting range of neural targets is now being actively pursed for the acute and preventive management of migraine."
        },
        {
            "id": "InternalMed_Harrison_30134",
            "title": "InternalMed_Harrison",
            "content": "Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Both the severity and duration of a migraine attack can be reduced significantly by NSAIDs (Table 447-4). Indeed, many undiagnosed migraineurs self-treat with nonprescription NSAIDs. A general consensus is that NSAIDs are most effective when taken early in the migraine attack. However, the effectiveness of these agents in migraine is usually less than optimal in moderate or severe migraine attacks. The combination of acetaminophen, aspirin, and caffeine has been approved for use by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate migraine. The combination of aspirin and metoclopramide has been shown to be comparable to a single dose of oral sumatriptan. Important side effects of NSAIDs include dyspepsia and gastrointestinal irritation. Oral Stimulation of 5-HT receptors can stop an acute migraine attack. Ergotamine and dihydroergotamine are nonselective receptor"
        },
        {
            "id": "InternalMed_Harrison_1429",
            "title": "InternalMed_Harrison",
            "content": "overdiagnosed and inappropriately managed. Migraine and other primary headache types are not \u201cvascular headaches\u201d; these disorders do not reliably manifest vascular changes, and treatment outcomes cannot be predicted by vascular effects. Migraine is a brain disorder and is best understood and managed as such."
        },
        {
            "id": "Neurology_Adams_1357",
            "title": "Neurology_Adams",
            "content": "migraine-associated stroke. The uncertain but potential role of antimigraine medications in producing stroke is discussed further on in the section on treatment. Estrogen medications have also been implicated in stroke in some women migraineurs. The complex relationship between acute stroke and the use of triptans or ergots for the treatment of migraine is addressed in a later section."
        },
        {
            "id": "InternalMed_Harrison_30137",
            "title": "InternalMed_Harrison",
            "content": "Unfortunately, monotherapy with a selective oral 5-HT recep tor agonist does not result in rapid, consistent, and complete relief of migraine in all patients. Triptans are generally not effective in migraine with aura unless given after the aura is completed and the headache initiated. Side effects are common, although often mild and transient. Moreover, 5-HT receptor agonists are contraindi cated in individuals with a history of cardiovascular and cerebrovascular disease. Recurrence of headache, within usual time course of an attack, is another important limitation of triptan use and occurs at least occasionally in most patients. Evidence from randomized controlled trials show that coadministration of a longer-acting NSAID, naproxen 500 mg, with sumatriptan will augment the initial effect of sumatriptan and, importantly, reduce rates of headache recurrence."
        },
        {
            "id": "Neurology_Adams_1397",
            "title": "Neurology_Adams",
            "content": "In individuals with frequent migrainous attacks, efforts at prevention are worthwhile. The survey by Lipton and colleagues, found approximately one-fourth of patients were appropriate for some form of prophylactic treatment on the basis of the frequency and severity of their headaches, usually more than one severe episode per week. The most effective agents have been beta-adrenergic blockers, certain antiepileptic drugs, and tricyclic antidepressants. Often, comorbidities such as depression, hypertension, epilepsy, or coronary artery disease guide the choice among these three classes of drugs. Some headache specialists have expressed the opinion that amitryptiline may be more effective if headaches are very frequent and that propranolol is more effective if severity of headaches is the concern. Ziegler and colleagues found propranolol and amityrptiline to be equally effective as preventive measures."
        },
        {
            "id": "Pharmacology_Katzung_1713",
            "title": "Pharmacology_Katzung",
            "content": "The mechanisms of action of drugs used in migraine are poorly understood, in part because they include such a wide variety of drug groups and actions. In addition to the triptans, these include ergot alkaloids, nonsteroidal anti-inflammatory analgesic agents, \u03b2-adrenoceptor blockers, calcium channel blockers, tricyclic antidepressants and SSRIs, and several antiseizure agents. Furthermore, some of these drug groups are effective only for prophylaxis and not for the acute attack."
        },
        {
            "id": "Pharmacology_Katzung_1741",
            "title": "Pharmacology_Katzung",
            "content": "A. Migraine Ergot derivatives are highly specific for migraine pain; they are not analgesic for any other condition. Although the triptan drugs discussed above are preferred by most clinicians and patients, traditional therapy with ergotamine can also be effective when given during the prodrome of an attack; it becomes progressively less effective if delayed. Ergotamine tartrate is available for oral, sub-lingual, rectal suppository, and inhaler use. It is often combined with caffeine (100 mg caffeine for each 1 mg ergotamine tartrate) to facilitate absorption of the ergot alkaloid."
        },
        {
            "id": "Neurology_Adams_1388",
            "title": "Neurology_Adams",
            "content": "A large and often cited meta-analysis of the available drugs in 53 separate trials conducted by Ferrari and colleagues (2001) found modest differences in overall efficacy between drugs. Loder has given a tabulated comparison of the main drugs for migraine and a review of their use in routine situations."
        },
        {
            "id": "InternalMed_Harrison_1442",
            "title": "InternalMed_Harrison",
            "content": "APPROACH TO THE PATIENT: The first step in the management of patients with CDH is to diagnose any secondary headache and treat that problem (Table 21-3). This can sometimes be a challenge where the underlying cause triggers a worsening of a primary headache. For patients with primary headaches, diagnosis of the headache type will guide therapy. Preventive treatments such as tricyclics, either amitriptyline or nortriptyline at doses up to 1 mg/kg, are very useful in patients with CDH arising from migraine or tension-type headache or where the secondary cause has activated the underlying primary headache. Tricyclics are started in low doses (10\u201325 mg) daily and may be given 12 h before the expected time of awakening in order to avoid excess morning sleepiness. Anticonvulsants, such as topiramate, valproate, flunarizine (not available in the United States), and candesartan are also useful in migraine."
        },
        {
            "id": "Pharmacology_Katzung_1717",
            "title": "Pharmacology_Katzung",
            "content": "Treatment (P = placebo, S = sumatriptan) FIGURE 16\u20133 Effects of sumatriptan (734 patients) or placebo (370 patients) on symptoms of acute migraine headache 60 minutes after injection of 6 mg subcutaneously. All differences between placebo and sumatriptan were statistically significant. (Data from Cady RK et al: Treatment of acute migraine with subcutaneous sumatriptan. JAMA for 5-HT1D and 5-HT1B receptors; the similarity of the triptan 1991;265:2831.) TABLE 16\u20136 Pharmacokinetics of triptans."
        },
        {
            "id": "Neurology_Adams_1344",
            "title": "Neurology_Adams",
            "content": "acting nonsteroidal anti-inflammatory drugs, magnesium, corticosteroids, or dihydroergotamine intravenous infusion in selected patients (see further on for details of treatment). In all likelihood, the patient has already been treated unsuccessfully with several medications and furthermore, the widely used serotonin agonist (\u201ctriptan\u201d) medications are less likely to be helpful at this later stage of migraine."
        },
        {
            "id": "InternalMed_Harrison_30149",
            "title": "InternalMed_Harrison",
            "content": "The probability of success with any one of the antimigraine drugs is 50\u201375%. Many patients are managed adequately with low-dose amitriptyline, propranolol, candesartan, topiramate, or valproate. If these agents fail or lead to unacceptable side effects, second-line agents such as methysergide or phenelzine can be used. Once effective stabilization is achieved, the drug is continued for ~6 months and then slowly tapered to assess the continued need. Many patients are able to discontinue medication and experience fewer and milder attacks for long periods, suggesting that these drugs may alter the natural history of migraine."
        },
        {
            "id": "Neurology_Adams_1395",
            "title": "Neurology_Adams",
            "content": "Intravenous and oral corticosteroids have been found anecdotally to be useful in refractory cases and as a means of terminating migraine status. In a randomized trial of intravenous dexamethasone 10 mg in an emergency department setting, Friedman et al found no benefit. As an alternative to steroids and more commonly used nonsteroidal agents, Weatherall and colleagues used intravenous aspirin (lysine acetylsalicylate, 1 g, repeated up to five times) with reasonably good effect in inpatient management of migraine and other headache disorders. We have determined that this agent is difficult to obtain from our hospital pharmacies."
        },
        {
            "id": "InternalMed_Harrison_30135",
            "title": "InternalMed_Harrison",
            "content": "Oral Stimulation of 5-HT receptors can stop an acute migraine attack. Ergotamine and dihydroergotamine are nonselective receptor INSTRUCTIONS: Please answer the following questions about ALL headaches you have had FIGURE 447-4 The Migraine Disability Assessment Score (MIDAS) Questionnaire. agonists, whereas the triptans are selective 5-HT receptor ago nists. A variety of triptans, 5-HT receptor agonists\u2014sumatriptan, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, and zolmitriptan\u2014are now available for the treatment of migraine."
        },
        {
            "id": "Pediatrics_Nelson_3798",
            "title": "Pediatrics_Nelson",
            "content": "Treating migraines requires an individually tailored regimen to address the frequency, severity, and disability produced by the headache. Intermittent symptomatic, or abortive, analgesics are the mainstay for treatment of infrequent, intense episodes of migraine. Symptomatic therapy requires early administration of an analgesic, rest, and sleep in a quiet, dark room. Acetaminophen or a nonsteroidal anti-inflammatory drug such as ibuprofen or naproxen sodium is often effective. Hydration and antiemetics are also useful adjunctive therapies. If these first-line medications are insufficient, triptan agents may be considered. Triptans, available in injectable, nasal spray, oral disintegrating, and tablet form, are serotonin receptor agonists that may alleviate migraine symptoms promptly. Triptans are contraindicated for patients with focal neurological deficits associated with their migraines or signs consistent with basilar migraine (syncope) because of the risk of stroke."
        },
        {
            "id": "Pharmacology_Katzung_1711",
            "title": "Pharmacology_Katzung",
            "content": "Migraine involves the trigeminal nerve distribution to intra-cranial (and possibly extracranial) arteries. These nerves release TABLE 16\u20135 Antiobesity drugs and their effects. Liraglutide GLP-1 agonist Decreases appetite 3 mg/d SC Nausea, vomiting, pancreatitis Lorcaserin 5-HT2c agonist Decreases appetite 10 mg PO BID Headache, nausea, dry mouth, dizziness, constipation Naltrexone/ Opioid antagonist Unknown 32 mg/ Headache, nausea, dizziness, constipation bupropion + antidepressant Phentermine Sympathomimetic Norepinephrine release in CNS 30\u201337.5 mg/d PO Increased BP, HR; arrhythmias, insomnia, anxiety"
        },
        {
            "id": "InternalMed_Harrison_30125",
            "title": "InternalMed_Harrison",
            "content": "A headache diary can often be helpful in making the diagnosis; this is also helpful in assessing disability and the frequency of treatment for acute attacks. Patients with episodes of migraine that occur daily or near-daily are considered to have chronic migraine (see \u201cChronic Daily Headache\u201d in Chap. 21). Migraine must be differentiated from tension-type headache (discussed below), the most common primary headache syndrome seen in the population. Migraine has several forms that have been defined (Table 447-1): migraine with and without aura and chronic migraine, the latter occurring 15 days or more a month, as the most important. Migraine at its most basic level is headache with associated features, and tension-type headache is headache that is featureless. Most patients with disabling headache probably have migraine."
        },
        {
            "id": "Pharmacology_Katzung_1719",
            "title": "Pharmacology_Katzung",
            "content": "several doses may be required during a prolonged migraine attack, but their adverse effects limit the maximum safe daily dosage. Naratriptan and eletriptan are contraindicated in patients with severe hepatic or renal impairment or peripheral vascular syndromes; frovatriptan in patients with peripheral vascular disease; and zolmitriptan in patients with Wolff-Parkinson-White syndrome. The brand name triptans are extremely expensive; thus generic sumatriptan should be used whenever possible."
        },
        {
            "id": "Neurology_Adams_1281",
            "title": "Neurology_Adams",
            "content": "With regard to characteristic temporal patterns, migraine of the typical type usually has its onset in the early morning hours or in the daytime, reaches its peak of severity over several to 30 min, and lasts, unless treated, for 4 to 24 h, occasionally longer. Often, it is terminated by sleep. A migrainous patient having several attacks per week usually proves to have a chronic form of migraine or a combination of migraine and analgesic \u201coveruse headache,\u201d meaning that the headache returns when the effect of the drug has worn off, or rarely, some unexpected intracranial lesion. By contrast, cluster headache is characterized by the occurrence of unbearably severe unilateral orbitotemporal pain coming on within 1 or 2 h after falling asleep or at predictable times during the day and recurring nightly or daily for a period of several weeks to months; usually an individual attack of \u201ccluster\u201d dissipates in 30 to 45 min but may occasionally last several hours. The headache of intracranial"
        },
        {
            "id": "Neurology_Adams_1399",
            "title": "Neurology_Adams",
            "content": "Alternatives, depending upon other comorbidities, are an antiepileptic medication, or our preference, a tricyclic antidepressant. Valproic acid 250 mg taken three to four times daily, other antiepileptic drug such as topiramate, or amitriptyline, 25 to 125 mg nightly may be tried. The newer antidepressants (e.g., specific serotonin reuptake inhibitors) are not as effective and may even cause headache in our experience. If these three main approaches are unsuccessful, calcium channel blockers (e.g., verapamil, 320 to 480 mg/d; nifedipine, 90 to 360 mg/d) are also reportedly effective in decreasing the frequency and severity of migraine attacks in some patients, but there is typically a lag of several weeks before benefit is attained and our success with them has been limited. Indomethacin, 150 to 200 mg/d; and cyproheptadine, 4 to 16 mg/nightly are found to be helpful in some patients and may be particularly useful in preventing predictable attacks of perimenstrual migraine."
        },
        {
            "id": "Pharmacology_Katzung_1742",
            "title": "Pharmacology_Katzung",
            "content": "The vasoconstriction induced by ergotamine is long-lasting and cumulative when the drug is taken repeatedly, as in a severe migraine attack. Therefore, patients must be carefully informed that no more than 6 mg of the oral preparation may be taken for each attack and no more than 10 mg per week. For very severe attacks, ergotamine tartrate, 0.25\u20130.5 mg, may be given intravenously or intramuscularly. Dihydroergotamine, 0.5\u20131 mg intravenously, is favored by some clinicians for treatment of intractable migraine. Intranasal dihydroergotamine may also be effective. Methysergide, which was used for migraine prophylaxis in the past, was withdrawn because of toxicity, see below. B. Hyperprolactinemia"
        },
        {
            "id": "InternalMed_Harrison_30143",
            "title": "InternalMed_Harrison",
            "content": "Naratriptan 2.5 mg PO Frovatriptan 2.5 mg PO usually with caffeine) Naratriptan 2.5 mg PO Almotriptan 12.5 mg PO Tolerating acute treatments poorly Naratriptan 2.5 mg Almotriptan 12.5 mg Dihydroergotamine 1 mg IM Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs. as \u201cpossibly\u201d effective in the treatment of migraine. Because the clinical studies demonstrating the efficacy of this combination analgesic in migraine predated the clinical trial methodologies used with the triptans, it is difficult to compare the efficacy of this sympathomimetic compound to other agents. Nasal A nasal preparation of butorphanol is available for the treatment of acute pain. As with all opioids, the use of nasal butorphanol has little role in migraine treatment."
        },
        {
            "id": "InternalMed_Harrison_30119",
            "title": "InternalMed_Harrison",
            "content": "Pharmacologic and other data point to the involvement of the neurotransmitter 5-hydroxytryptamine (5-HT; also known as serotonin) in migraines. Approximately 60 years ago, methysergide was found to antagonize certain peripheral actions of 5-HT and was introduced as the first drug capable of preventing migraine attacks. The triptans were designed to stimulate selectively subpopulations of 5-HT receptors; at least 14 different 5-HT receptors exist in humans. The triptans are potent agonists of 5-HT1B and 5-HT1D receptors, and some are active at the 5-HT1F receptors; the latter\u2019s exclusive agonists are called ditans. Triptans arrest nerve signaling in the nociceptive pathways of the trigeminovascular system, at least in the trigeminal nucleus caudalis and trigeminal sensory thalamus, in addition to cranial vasoconstriction, while ditans, now shown conclusively to be effective in acute migraine, act only at neural targets. An interesting range of neural targets is now being actively"
        }
    ],
    "scores": [
        0.03776536592070573,
        0.03758117124109821,
        0.03650210144847602,
        0.03637708504965142,
        0.0344805441846741,
        0.03392592592592593,
        0.03378815366008651,
        0.0327134974890042,
        0.032657542428108435,
        0.03218592177079366,
        0.031274954445686155,
        0.03115881444013823,
        0.02847088804719626,
        0.028469689435616015,
        0.027834992968450364,
        0.027694558024801846,
        0.027654979615244577,
        0.027202635360691313,
        0.026830528333283386,
        0.026207555819502185,
        0.026110090018588526,
        0.025878529912642778,
        0.02514217162104486,
        0.02465723253124828,
        0.022843407086222713,
        0.022838273421624273,
        0.022120073944505464,
        0.021983123399771765,
        0.021824152858635617,
        0.02181650935850264,
        0.021783737387648695,
        0.020804885148724462
    ]
}